• Product NameRecombinant Murine Heparin-binding EGF-like Growth Factor
• Host SpeciesEscherichia coli.
• Purification> 97 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/c 3T3 cells is less than 1 ng/ml, corresponding to a specific activity of > 1.0 x10⁶ IU/mg.
• EndotoxinLess than 1 EU/ug of rMuHB-EGF as determined by LAL method.
• Alternative Names    HBEGF, DT-R
• UniprotQ06186
• Gene ID15200
• Calculated MW Approximately 9.8 kDa, a single non-glycosylated polypeptide chain containing 86 amino acids.
• Target Sequence DLEGTDLNLF KVAFSSKPQG LATPSKERNG KKKKKGKGLG KKRDPCLRKY KDYCIHGECR YLQEFRTPSC KCLPGYHGHR CHGLTL
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in 10 mM PB, 500 mM NaCl, pH7.4.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

Heparin-binding epidermal growth factor (HB-EGF)-like growth factor (EGF) is found in cerebral neurons. Its expression is increased after hypoxic or ischemic injury, which also stimulates neurogenesis. HB-EGF has been implicated as a participant in a variety of normal physiological processes such as blastocyst implantation and wound healing, and in pathological processes such as tumor growth, SMC hyperplasia and atherosclerosis. The protein is an 87 amino acid mitogenic and chemotactic glycoprotein containing an EGF-like domain with six conserved cysteine residues. Mouse HB-EGF shares about 73 % a.a. sequence identity with human HB-EGF.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting